Table 4.
Univariate and multivariate analyses of factors associated with overall survival.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P1 | HR (95%CI) | P2 | |
| Gender female vs. male | 0.62 (0.22, 1.71) | 0.355 | ||
| Age, year > vs.≤ 55 | 1.26 (0.77, 2.07) | 0.358 | ||
| ECOG-PS 0 vs. 1 | 0.77 (0.40, 1.48) | 0.428 | ||
| NLR ≤ vs. > 3.11 | 0.51 (0.30, 0.86) | 0.012 | 0.52 (0.31, 0.89) | 0.016 |
| ALBI grade 1 vs. 2 | 0.86 (0.52, 1.41) | 0.551 | ||
| Child-Pugh 5 vs. 6 & 7 | 0.92 (0.50, 1.69) | 0.782 | ||
| AFP, ng/ml ≤ vs. > 400 | 0.51 (0.31, 0.85) | 0.009 | 0.49 (0.29, 0.83) | 0.008 |
| DCP, mAU/ml ≤ vs. > 664 | 0.61 (0.37, 1.00) | 0.048 | 0.90 (0.53, 1.54) | 0.699 |
| Target tumor size, cm ≤ vs. > 7.5 | 0.94 (0.57, 1.54) | 0.807 | ||
| Target tumor number 1 vs. ≥ 1 | 1.02 (0.56, 1.85) | 0.949 | ||
| MVI absent vs. present | 0.63 (0.38, 1.05) | 0.076 | 0.57 (0.34, 0.98) | 0.041 |
| EHS absent vs. present | 0.82 (0.50, 1.36) | 0.449 | ||
| BCLC stage B vs. C | 0.96 (0.56, 1.65) | 0.8912 | ||
| Treatment option Combination therapy vs. TACE | 0.23 (0.12, 0.42) | <0.001 | 0.18 (0.10, 0.35) | <0.001 |
The bold values highlighted the factors with significant difference.
P1 value was calculated with log-rank test. Any variables that were statistically significant at P < 0.1 in the univariate analysis were used in multivariate analyses using Cox regression analysis.
P2 value was calculated by multivariable Cox proportional-hazards analysis.
ECOG-PS, Eastern Cooperative Oncology Group performance status; NLR, neutrophil-to-lymphocyte ratio; ALBI grade albumin-bilirubin grade; AFP alpha-fetoprotein; DCP, Des-gamma carboxy prothrombin; MVI, macrovascular invasion; EHS, extrahepatic spread; BCLC, Barcelona Clinic Liver Cancer.